Humacyte awards director Coward 125,000 stock options

The first 25% becomes exercisable on October 6, 2027, with monthly vesting thereafter through October 6, 2030.

Rhea-AI Filing Summary

Humacyte, Inc. director D. Scott Coward received an award of 125,000 stock options on October 6, 2026, with an exercise price of $0.478 per share and an expiration date of October 6, 2036. The first 25% becomes exercisable on October 6, 2027; thereafter, 1/48 becomes exercisable on the 6th of each month, with the options fully vested on October 6, 2030.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider COWARD D SCOTT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy) F1	125,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 125,000 contracts (Direct)

Footnotes (1)

1. F1. The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030.

Key Figures

Stock options awarded: 125,000 stock options Exercise price: $0.478 per share First exercisable portion: 25% +3 more

6 metrics

Stock options awarded 125,000 stock options Award to director D. Scott Coward on October 6, 2026

Exercise price $0.478 per share Awarded stock options

First exercisable portion 25% Becomes exercisable on October 6, 2027

Monthly exercisable portion 1/48 of the option Becomes exercisable on the 6th day of each month after the first 25%

Full vesting date October 6, 2030 Stock options become fully vested

Expiration date October 6, 2036 Awarded stock options

Key Terms

Stock Options (right to buy), exercisable, fully vested

3 terms

Stock Options (right to buy) financial

"125,000 Stock Options (right to buy)"

exercisable financial

"The first 25% of the option becomes exercisable"

fully vested financial

"the option becoming fully vested on October 6, 2030"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Humacyte (HUMA) director D. Scott Coward receive?

D. Scott Coward received 125,000 stock options on October 6, 2026, with an exercise price of $0.478 per share.

When do D. Scott Coward's HUMA options become exercisable and fully vest?

The first 25% becomes exercisable on October 6, 2027. After that, 1/48 becomes exercisable on the 6th of each month, with the options fully vested on October 6, 2030.

When do D. Scott Coward's HUMA stock options expire?

The options expire on October 6, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 04:06 PM Accepted by SEC EDGAR 10/07/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COWARD D SCOTT

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.478	10/06/2026		A		125,000		(1)	10/06/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030.

	/s/ Scott D. Coward by Dale A. Sander as Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)